Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: possible risks and benefits.
The toxicity of standard triple-therapy immunosuppressive regimens has been identified as a possible factor in the failure to extend long-term renal allograft survival despite a continued decline of acute rejection rates. The result has been increasing focus on the use of mycophenolate mofetil-based, low-toxicity immunosuppressive regimens, which have been shown in randomized studies to have the potential to improve long-term graft survival. This Clinical Update discusses the likely risks and benefits for switching the immunosuppressive regimen in clinical practice.
Meier-Kriesche
Herwig-Ulf
HU
University of Florida College of Medicine, Gainesville, Florida, USA.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D065095:Calcineurin Inhibitors; D002318:Cardiovascular Diseases / Q000209:etiology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid